<DOC>
	<DOCNO>NCT01426880</DOCNO>
	<brief_summary>Study participant primary breast cancer receive standard chemotherapy anthracycline taxane well trastuzumab case HER2-positive tumor dose duration concordance current treatment guideline . Patients receive benefit addition currently neoadjuvant set registered medication lapatinib bevacizumab significant increase cure ( pCR ) rate report previous phase III study . Patients randomize carboplatin receive addition describe backbone therapy potentially active agent suggest synergy efficacy chemotherapy well targeted agent . Patients might risk increase toxicity due add agent additional burden due investigation require study participation . However , due severity underlie disease high risk relapse death due stage disease , increase toxicity burden appear less relevant compare potential high efficacy finally cure rate incorporate treatment .</brief_summary>
	<brief_title>Addition Carboplatin Neoadjuvant Therapy Triple-negative HER2-positive Early Breast Cancer</brief_title>
	<detailed_description>Anthracycline/taxane base combination chemotherapy least 18 week represent standard care neoadjuvant setting . In HER2-positive disease trastuzumab give simultaneously chemotherapy . Recent data Neo-Altto Neosphere trial suggest dual blockage HER2 receptor e.g . trastuzumab lapatinib reach significantly high pCR rate trastuzumab alone therefore represent treatment back-bone new neoadjuvant trial . A preplanned subgroup analysis GeparQuinto study demonstrate TNBC addition bevacizumab result significant increase pCR rate ( HR 1.4 ) . Having good cardiac tolerability profile compare conventional anthracyclines , non-pegylated liposomal encapsulate doxorubicin ( NPLD ) Myocet® might provide possibility combine taxane , anthracycline , platinum salt well targeted agent double HER2 blockage bevacizumab .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1.Written informed consent study procedure accord local regulatory requirement prior begin specific protocol procedure . 2.Complete baseline documentation must submit via Medcodes® approve GBG Forschungs GmbH . 3.Unilateral bilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration sufficient . Incisional biopsy allow . In case bilateral cancer , investigator decide prospectively side evaluated primary endpoint . 4.Tumor lesion breast palpable size ≥ 2 cm sonographical size ≥ 1 cm maximum diameter . The lesion measurable two dimension , preferably sonography . In case inflammatory disease , extent inflammation use measurable lesion . 5.Patients follow stage disease : cT2 cT4ad cT1c cN+ pNSLN+ 6.In patient multifocal multicentric breast cancer , large lesion measure . 7.Centrally confirm ER/PR/HER2 Ki67 status detect core biopsy . ER/PR positive define &gt; 1 % stained cell HER2positive define HercepTest IHC 3+ FISH ratio ≥ 2.2 . Formalinfixed , paraffinembedded ( FFPE ) breast tissue core biopsy therefore send Dept . Pathology Charité , Berlin prior randomization . 8.Age ≥ 18 year . 9.Karnofsky Performance status index ≥ 80 % . 10.Normal cardiac function must confirm ECG cardiac ultrasound ( LVEF shorten fraction ) within 3 month prior randomization . LVEF must 55 % . 11.Laboratory requirement : Hematology Absolute neutrophil count ( ANC ) ≥ 2.0 x 109 / L Platelets ≥ 100 x 109 / L Hemoglobin ≥ 10 g/dL ( ≥ 6.2 mmol/L ) Hepatic function Total bilirubin &lt; 1.5x UNL ASAT ( SGOT ) ALAT ( SGPT ) ≤ 1.5x UNL Alkaline phosphatase ≤ 2.5x UNL . Renal function Creatinine ≤ 175 µmol/L ( 2 mg/dL ) &lt; 1.5x UNL Proteinuria : Urine dipstick proteinuria &lt; 2+ . Patients discover ≥ 2+ proteinuria dipstick urinalysis undergo 24hour urine collection must demonstrate ≤ 1 g protein 24 hour . If creatinine 140 175 umol/L ( 1.62.0 mg/dL ) , creatinine clearance ( calculate measure ) ≥ 45 mL/min . 12.Negative pregnancy test ( urine serum ) within 14 day prior randomization woman childbearing potential . 13.Complete stag workup within 3 month prior randomization . All patient must bilateral mammography , breast ultrasound ( ≤ 21 day ) , breast MRI ( optional ) , chest Xray ( PA lateral ) , abdominal ultrasound CT scan MRI , bone scan do . In case positive bone scan , bone Xray ( CT MRI ) mandatory . Other test may perform clinically indicate . 14.Patients must available compliant central diagnostics , treatment followup . 1 . Prior chemotherapy malignancy . 2 . Prior radiation therapy breast cancer . 3 . Pregnant lactating patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure ( barrier method , intrauterine contraceptive device , sterilization ) study treatment . 4 . Inadequate general condition ( fit anthracyclinetaxanetargeted agentsbased chemotherapy ) . 5 . Previous malignant disease diseasefree less 5 year ( except CIS cervix nonmelanomatous skin cancer ) . 6 . Known suspected congestive heart failure ( &gt; NYHA I ) / coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , uncontrolled poorly control arterial hypertension ( i.e . BP &gt; 160 / 90 mm Hg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease . 7 . Previous thromboembolic event ( except thrombophily screen negative ) . 8 . Known hemorrhagic diathesis coagulopathy increase bleeding risk . 9 . History significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent 10 . Preexisting motor sensory neuropathy severity ≥ grade 2 NCICTC criterion v 4.0 . 11 . Currently active infection . 12 . Active peptic ulcer . 13 . Incomplete wound heal unhealed bone fracture . 14 . Disease significantly affect gastrointestinal function , e.g . malabsorption syndrome , resection stomach small bowel , ulcerative colitis . 15 . History abdominal fistula grade 4 nongastrointestinal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment . 16 . Severe pulmonary condition / illness . 17 . Major surgery within last 28 day anticipation need major surgery study treatment bevacizumab . Minor surgery include insertion indwell catheter sentinel lymph node biopsy within 24 h prior chemotherapy . 18 . Definite contraindication use corticosteroid except inhalative corticoid . 19 . Known hypersensitivity reaction one compound incorporated substance use protocol ; 20 . Concurrent treatment : chronic corticosteroid unless initiate &gt; 6 month prior study entry low dose ( ≤ 10 mg methylprednisolone equivalent ) . sex hormone . Prior treatment must stop study entry . virostatic agent like sorivudine analog like brivudine , concurrent treatment aminoglycosides . anticoagulant : heparin , warfarin well acetylic acid ( e.g . Aspirin® ) dose &gt; 325 mg/day clopidogrel dose &gt; 75 mg/day . experimental drug anticancer therapy . drug recognize strong inhibitor inducer isoenzyme CYP3A , e.g . Rifabutin , Rifampicin , Clarithromycin , Ketoconazole , Itraconazole , Ritonavir , Telithromycin , Erythromycin , Verapamil , Diltiazem within last 5 day expect need treatment study participation . 21 . Participation another clinical trial investigational , market drug within 30 day prior study entry . 22 . Male patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GBG</keyword>
	<keyword>German Breast Group</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>Tubular breast cancer stage II</keyword>
	<keyword>Mucinous breast cancer stage II</keyword>
	<keyword>Invasive ductal breast cancer</keyword>
	<keyword>Tubular breast cancer stage III</keyword>
	<keyword>HER-2 positive breast cancer</keyword>
	<keyword>Inflammatory breast cancer stage IV</keyword>
	<keyword>Inflammatory breast cancer</keyword>
</DOC>